Effect comparison of domestic rapamycin eluting stent versus imported rapamycin eluting stent in patients with coronary atherosclerotic heart disease

Objective：To compare the application effects of domestic polymer based rapamycin eluting stent (Firebird 2) and imported polymer based rapamycin eluting stent (Cypher Select) in percutaneous coronary intervention for patients with coronary atherosclerotic heart disease (CHD). Methods：CHD patients who were treated with polymer based rapamycin eluting stent from May 2010 to December 2011 at Shanghai Sixth People’s Hospital were enrolled. Patients were divided into the Firebird 2 group (n=139) and the Cypher group(n=125). The followup period was 2540 months, average (32.54±3.90)months. Major adverse cardiovascular events (MACE, include cardiac death, nonfatal myocardial infarction, revascularization), instent restenosis, and definite stent thrombosis during followup period were collected and analyzed. Results：Compared with Cypher group, patients in Firebird 2 group had lower rate of male patients (P＜0.05), higher levels of Nterminal proBtype natriuretic peptide (NT proBNP), longer target lesion, and the number of stents implanted per lesion was greater (P＜0.05). Incidences of cardiac death(4.3% vs 3.2%), nonfatal myocardial infarction(1.4% vs 1.6%), revascularization(4.3% vs 5.6%), MACE(9.4% vs 8.8%), instent restenosis and definite stent thrombosis all had no significant differences between the two groups. Logistic regression analysis showed that age(OR=1.11，95%CI 1.051.18，P=0.000), diabetes (OR=2.70，95%CI 1.027.15, P=0.045) were independent risk factors of MACE, stent type(OR=0.88，95%CI 0.342.24, P=0.782) was not an independent risk factor of MACE. Conclusions：Firebird 2 rapamycin eluting stent and Cypher rapamycin eluting stent have similar longterm clinical efficacy and safety in the treatment of CHD.